Evidence map›Paper›PMID 42528542›Full record

ArticleFrontiers in immunology2026

Emodin treatment is associated with enhanced resistance to

Yuqing Liu, Shuaijie Sun, Juan Du, Bianzhi Liu, Guoxi Li, Guangqing Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuqing LiuCollege of Animal Science and Technology, Henan Agricultural University, Zhengzhou, China.
Shuaijie SunHenan Academy of Fishery Sciences, Henan Academy of Agricultural Sciences, Zhengzhou, China.
Juan DuInstitute of Maternal and Child Health, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Bianzhi LiuCollege of Animal Science and Technology, Henan Agricultural University, Zhengzhou, China.
Guoxi LiCollege of Animal Science and Technology, Henan Agricultural University, Zhengzhou, China.
Guangqing YuCollege of Animal Science and Technology, Henan Agricultural University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Yellow River carp were used as a model, and multi-omics approaches (including 16S rRNA/ITS sequencing and untargeted metabolomics) were employed, along with evaluations of survival rate, hepatic and intestinal histopathology, quorum sensing-related virulence gene expression, and serum IgM and lysozyme activities. Results: Emodin treatment improved survival rate, alleviated pathological damage in the liver and intestine, downregulated quorum sensing-related virulence genes ( Discussion: Emodin treatment was associated with enhanced anti-infection ability in Yellow River carp, concomitant with significant alterations in the intestinal microbiota, metabolism, and immune responses, underscoring its great potential as an environmentally friendly immunostimulant in aquaculture.

Indexed as

Aeromonas hydrophilaCarpsDisease ResistanceEmodinFish DiseasesGastrointestinal MicrobiomeGram-Negative Bacterial InfectionsAnimalsMultiomicsEmodinAeromonas hydrophilaemodingut microbiotaimmunologyYellow River carp

Identifiers

PMID42528542
PMCPMC13414214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.